Defining Product Direction for a Next-Generation ACDF System
A spinal implant manufacturer needed to define a next-generation ACDF system for an established $200 million cervical implant business competing in a mature, crowded category.
I led the engagement across competitive intelligence, surgeon insight, and product definition, helping engineering and marketing decide where to maintain parity, reduce cost, and selectively differentiate.
The resulting requirements framework gave the organization a clear foundation for development across more than 50 components while focusing investment on improvements that could create meaningful near-term value.
Keywords: Product Strategy · Competitive Intelligence · Requirements Definition · Clinical Insight · Product Definition · Cross-Functional Leadership
Project Info
Client: A Spinal Implant Manufacturer
Time: 2023, 4 Months
Role: Project Lead, Strategist, Principal Investigator
Project Overview
-
We began by developing a shared understanding of the existing implant system, the ACDF procedure, the competitive category, and the decisions facing the product team.
I brought engineering and marketing stakeholders together to surface assumptions, identify knowledge gaps, and clarify what the organization needed to understand before defining its next-generation offering.
This established the clinical and business criteria we would use to evaluate future directions.
-
I worked with the client team to define the competitive set and the technical, experiential, and market dimensions most important to understand.
I directed an industrial designer and human factors engineer in analyzing more than a dozen systems, including established market leaders and competitors pursuing newer approaches.
We translated the analysis into a shared perspective on technical parity, market positioning, and potential white space so engineering and marketing could make decisions from the same competitive picture.
-
I guided surgeon evaluation of the existing system through cadaver labs designed to expose workflow friction, latent needs, and opportunities for differentiation.
The most important conclusion was that surgeons already liked the procedure and did not perceive major shortcomings in the current system.
That changed the strategic question from how to fix a broken experience to where selective improvements could create differentiation without undermining what already worked.
-
I led the translation of the competitive and clinical evidence into a product requirements framework spanning more than fifty components and their associated features and attributes.
Working with engineering and marketing, we considered where the next-generation system needed to maintain parity, where cost could be reduced without degrading the experience, and where focused improvements could create meaningful differentiation.
A good-better-best framework helped the organization distinguish between requirements that simply met the market and areas where it could deliberately raise the bar.
Key Takeaways
Finding White Space in a Mature Market
The ACDF category was crowded with established competitors, making differentiation considerably more nuanced than introducing an entirely new capability.
Combining technical benchmarking with analysis of how competitors positioned their products revealed where offerings were converging and where meaningful strategic gaps remained.
This gave marketing and R&D a shared basis for deciding where the next-generation system should compete and differentiate.
Protecting What Already Works
The surgeon work challenged the assumption that meaningful innovation always begins with an obvious pain point.
Because users generally valued the existing procedure, the stronger strategy was to preserve what worked while identifying selective opportunities either to reduce cost or introduce targeted improvements that created additional value.
That conclusion helped focus investment on differentiation that mattered rather than change for its own sake.
Challenges
Getting to Specificity Quickly
The engagement combined a highly technical clinical subject with a relatively lean project scope.
I structured the work around iterative reviews, allowing the team to develop and validate portions of the competitive and clinical analysis before applying a repeatable framework across the broader system.
This approach allowed us to move efficiently from a complex body of evidence toward detailed product direction without losing strategic focus.